List of subsidised drugs

MOH provides drug subsidies at public hospitals, specialist outpatient clinics, and polyclinics. This ensures patients can access effective medications for common medical conditions in Singapore.

Last updated 31 March 2025

List of Drugs* (as of 1 April 2025)

*The drug availability at each healthcare institution varies, depending on the clinical conditions commonly managed by the institution and the drugs usually prescribed by the doctors.

Search the list

Active Ingredient(s)	Dosage Form	Strength(s)	Subsidy Class	Clinical Indication (where applicable)
Abacavir & Lamivudine	Tablet	Abacavir 600 mg + Lamivudine 300 mg	SDL
Abacavir, Dolutegravir & Lamivudine	Tablet	Abacavir 600 mg + Dolutegravir 50 mg + Lamivudine 300 mg	SDL
Abemaciclib	Tablet	50 mg, 100 mg, 150 mg	MAF	1) Abemaciclib in combination with an aromatase inhibitor as initial endocrine-based therapy for HR positive, HER2 negative, advanced or metastatic breast cancer. Pre/perimenopausal women treated with this combination could also receive a luteinizing hormone-releasing hormone agonist according to local clinical practice. 2) Abemaciclib in combination with fulvestrant for treating HR positive, HER2 negative, advanced or metastatic breast cancer in patients who have received prior endocrine therapy. Pre/perimenopausal women treated with this combination could also receive a luteinizing hormone-releasing hormone agonist according to local clinical practice. 3) Abemaciclib in combination with endocrine therapy for adjuvant treatment of patients with HR positive, HER2 negative, node-positive early breast cancer at high risk of recurrence. Maxiumum treatment duration: 2 years.
Abiraterone Acetate	Tablet	250 mg	SDL
Abrocitinib	Tablet	50 mg, 100 mg, 200 mg	MAF	Additional clinical criteria applies Treatment of moderate to severe atopic dermatitis (AD)
Absolute Alcohol	Injection	100%	SDL
Acalabrutinib	Capsule	100 mg	MAF	1) Monotherapy for previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in patients who are unsuitable for fludarabine-based therapy 2) Monotherapy for chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in patients who have received at least one prior therapy 3) Treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy
Acalabrutinib	Tablet	100 mg	MAF	1) Monotherapy for previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in patients who are unsuitable for fludarabine-based therapy 2) Monotherapy for chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in patients who have received at least one prior therapy 3) Treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy
Acetazolamide	Tablet	250 mg	SDL
Acetic acid	Ear drops	2%, 3%, 4%, 5%	SDL